Taiko Pharmaceutical Co.,ltd. Stock price
AI Insights on Taiko Pharmaceutical Co.,ltd.
Insights
Is Taiko Pharmaceutical Co.,ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,093 stocks worldwide.
Key metrics
Taiko Pharmaceutical Co.,ltd. Stock Analysis
Analyst Opinions
7 Analysts have issued a Taiko Pharmaceutical Co.,ltd. forecast:
Analyst Opinions
7 Analysts have issued a Taiko Pharmaceutical Co.,ltd. forecast:
Taiko Pharmaceutical Co.,ltd. Events
Upcoming Event
Don't miss a Thing! We will send you all news about Taiko Pharmaceutical Co.,ltd. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Taiko Pharmaceutical Co., Ltd. engages in the manufacture and sale of general medications particularly non-prescription gastrointestinal drugs and designated quasi drugs. The company is headquartered in Osaka, Osaka-Fu and currently employs 220 full-time employees. The company went IPO on 2009-03-18. The firm is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.
| Head office | Japan |
| CEO | Dr. Shibata |
| Employees | 220 |
| Website | www.seirogan.co.jp |


